Design and synthesis of some pyrazole derivatives of expected anti-inflammatory and analgesic activities

Medicinal Chemistry Research

Volumn 21, Issue 7, 2012, Pages 983-994

  Abd El Gawad, Nagwa M ^a   Hassan, Ghaneya S ^a   Georgey, Hanan Hanna ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Analgesic; Anti inflammatory; MOE; Pyrazoles

Indexed keywords

1 (2,4 DIMETHOXYPHENYL) 2 METHYL PROP 2 EN 1 ONE; 1 (2,4 DIMETHOXYPHENYL) 2 PHENYL ETHANONE; 1 (2,4 DIMETHOXYPHENYL) 2 PHENYL PROP 2 EN 1 ONE; 1 (4 CHLOROPHENYL) 5 (2,4 DIMETHOXYPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXYLIC ACID; 1 (4 CHLOROPHENYL) 5 (2,4 DIMETHOXYPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 1 (4 CHLOROPHENYL) 5 (2,4 DIMETHOXYPHENYL) 4 PHENYL 1H PYRAZOLE 3 CARBOXYLIC ACID; 1 (4 CHLOROPHENYL) 5 (2,4 DIMETHOXYPHENYL) 4 PHENYL 1H PYRAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 1,4 BENZOQUINONE; 2,4 DIOXO 3 PHENYL 4 (2,4 DIMETHOXYPHENYL)BUTANOIC ACID ETHYL ESTER; 3 (2,4 DIMETHOXYPHENYL) 4 METHYL 4,5 DIHYDRO 1H PYRAZOLE; 3 (2,4 DIMETHOXYPHENYL) 4 PHENYL 4,5 DIHYDRO 1H PYRAZOLE; 3 (2,4 DIMETHOXYPHENYL) N [(4 METHYLPHENYL)SULFONYL] 4 METHYL 4,5 DIHYDRO 1H PYRAZOL 1 CARBOXAMIDE; 3 (2,4 DIMETHOXYPHENYL) N [(4 METHYLPHENYL)SULFONYL] 4 PHENYL 4,5 DIHYDRO 1H PYRAZOL 1 CARBOXAMIDE; 3 METHYL 2,4 DIOXO 4 (2,4 DIMETHOXYPHENYL)BUTANOIC ACID ETHYL ESTER; 5 (2,4 DIMETHOXYPHENYL) 1,4 DIPHENYL 1H PYRAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; 5 (2,4 DIMETHOXYPHENYL) 4 METHYL 1 PHENYL 1H PYRAZOLE 3 CARBOXYLIC ACID ETHYL ESTER; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2; IBUPROFEN; N (4 CHLOROBENZOYL) 3 (2,4 DIMETHOXYPHENYL) 4 METHYL 4,5 DIHYDRO 1H PYRAZOL 1 THIOCARBOXAMIDE; N (4 CHLOROBENZOYL) 3 (2,4 DIMETHOXYPHENYL) 4 PHENYL 4,5 DIHYDRO 1H PYRAZOL 1 THIOCARBOXAMIDE; N [(4 CHLOROPHENYL)SULFONYL] 3 (2,4 DIMETHOXYPHENYL) 4 METHYL 4,5 DIHYDRO 1H PYRAZOL 1 CARBOXAMIDE; N [(4 CHLOROPHENYL)SULFONYL] 3 (2,4 DIMETHOXYPHENYL) 4 PHENYL 4,5 DIHYDRO 1H PYRAZOL 1 CARBOXAMIDE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; GASTRIC TOXICITY; MOLECULAR DOCKING; NONHUMAN; PAW EDEMA; RAT; SPECTROSCOPY; STOMACH ULCER; STRUCTURE ANALYSIS; TOXICITY; WRITHING TEST;

EID: 84861885034     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9606-4     Document Type: Article

References (34)

1. Abbas SE, Awadallah FM, Ibrahim NA, Gouda AM (2010) Novel substituted and fused pyrrolizine derivatives: synthesis, anti-inflammatory and ulcerogenecity studies. Eur J Med Chem 45:482-491
2. Alam MI, Baboota S, Kohli K, Ali J, Ahuja A (2009) Development and evaluation of transdermal patches of celecoxib. PDA J Pharm Sci Technol 63:429-437
3. Barsoum FF, Hosni HM, Girgis AS (2006) Novel bis(1-acyl-2-pyrazolines) of potential anti-inflammatory and molluscicidal properties. Bioorg Med Chem 14:3929-3937
4. Buck WB, Osweiter GD, Van Gelder AG (1976) Clinical and diagnostic veterinary toxicology, 2nd edn. Kendall/hunt Publishing Co., Iowa, p 5211
5. Cho NS, Shon HI (1991) Synthesis of 5-(aroylamino)-2-methyl-2H-1,2,4- thiazoliazol-3-ones by oxidative cyclisation of 1-aroyl-5-methyl-2-thiobiurets. J Heterocycl Chem 28:1645-1649
6. Collier HD, Dinnin LC, Johnson CA, Schneider C (1968) The abdominal response and its suppression by analgesic drugs in the mouse. Br J Pharmacol Ther 32:295-310
7. Cryer B (2005) NSAID-associated deaths: the rise and fall of NSAIDassociated GI mortality. Am J Gastroenterol 100:1694-1695
8. Finney DJ (1964) Statistical methods in biological assay. Charles Griffin and Company Ltd, London, p 597
9. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Nicolaides DN (2004) Natural and synthetic coumarin derivatives with antiinflammatory/antioxidant activities. Curr Pharm Des 10:3813-3833
10. James MW, Hawkey CJ (2003) Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. Br J Clin Pharmacol 56(2):146-155
11. Karthikeyan MS, Holla BS, Kumari NS (2007) Synthesis and antimicrobial studies on novel chloro-fluorine containing hydroxy pyrazolines. Eur J Med Chem 42:30-36
12. Lacerda RB, de Lima CK, da Silva LL, Romeiro NC, Miranda AL, Barreiro EJ, Fraga CA (2009) Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorg Med Chem 17:74-84
13. Lange JHM, Coolen HKAC, van Stuivenberg HH, Dijksman JAR, Herremans AHJ, Ronken E, Keizer HG, Tipker K, McCreary AC, Veerman W, Wals HC, Stork B, Verveer PC, den Hartog AP, de Jong NMJ, Adolfs TJP, Hoogendoorn J, Kruse CG (2004) Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarrypyrazolines as potent and selective CB1 cannabinoid receptor antagonists J. Med. Chem 17:627-643
14. Laufer S, Luik S (2010) Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors. Methods Mol Biol 644:91-116
15. Lazzaroni M, Bianchi Porro G (2004) Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther 2:48-58
16. Menozzi G, Merello L, Fossa P, Mosti L, Piana A, Mattioli F (2003) 4-substituted 1,5-diarylpyrazole, analogues of celecoxib: synthesis and preliminary evaluation of biological properties. Farmaco 58:795-808
17. Meshali M, El-Sabbah E, Foda A (1983) Effect of encapsulation of flufenamic acid with acrylic resins on its bioavailability and gastric ulcerogenic activity in rats. Acta Pharm Technol 29:217-230
18. Molecular Operating Environment (MOE) (2005) Version 2005.06, Chemical Computing Group, Inc., Montreal, Quebec, Canada. http://www.chemcomp.com
19. Mounier G, Guy C, Berthoux F, Beyens MN, Ratrema M, Ollagnier M (2006) Severe renal adverse events with arylcarboxylic nonsteroidal anti-inflammatory drugs: results of an eight-year French national survey. Therapie 61:255-266
20. Naesdal J, Brown K (2006) NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf 29:119-132
21. Patel MV, Bell R, Majest S, Henry R, Kolasa T (2004) Synthesis of 4,5-diaryl-1H-pyrazole-3-ol derivatives as potential COX-2 inhibitors. J Org Chem 69:7058-7065
22. Ramiz MM, El-Sayed WA, El-Tantawy AI, Abdel-Rahman AA (2010) Antimicrobial activity of new 4,6-disubstituted pyrimidine, pyrazoline, and pyran derivatives. Arch Pharm Res 33: 647-654
23. Rathish IG, Javed K, Ahmad S, Bano S, Alam MS, Pillai KK, Singh S, Bagchi V (2009) Synthesis and anti-inflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide. Bioorg Med Chem Lett 19:255-258
24. Reynold JEF (1993) Martindale, the extra pharmacopia, 30th edn. Pharmaceutical Press, London, p 1310
25. 1 on gastric secretion and ulcer formation in the rat. Gastroenterology 55:481-487
26. Sakya SM, Hou X, Minich ML, Rast B, Shavnya A, DeMello KM, Cheng H, Li J, Jaynes BH, MannDW, Petras CF, Seibel SB, Haven ML (2007) 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile. Bioorg Med Chem Lett 17:1067-1072
27. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM (2006) Association of selective and conventional nonsteroidal anti-inflammatory drugs with acute renal failure: a populationbased, nested case-control analysis. Am J Epidemiol 164:881-889
28. Shoman ME, Abdel-Aziz M, Aly OM, Farag HH, Morsy MA (2009) Synthesis and investigation of anti-inflammatory activity and gastric ulcerogenicity of novel nitric oxide-donating pyrazoline derivatives. Eur J Med Chem 44:3068-3076
29. Slotta KH, Heller H (1930) Ü ber β-phenyl-äthylamine, I. Mitteil.: Mezcalin und mezcalin-ähnliche substanzen. Ber 63:3029-3044
30. Sostres C, Gargallo CJ, Arroyo MT, Lanas A (2010) Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 24:121-132
31. Turan-Zitouni G, Chevallet P, Kiliç FS, Erol K (2000) Synthesis of some thiazolyl-pyrazoline derivatives and preliminary investigation of their hypotensive activity. Eur J Med Chem 35:635-641
32. Winter CA, Risley EA, Nuss GW (1962) Proceedings of the society for experimental biology and medicine. Proc Soc Exp Biol 544-547
33. Yanai H, Furutani N, Yoshida H, Tada N (2009) Myositis, vasculitis, hepatic dysfunction in adult-onset still's disease. Case Rep Med 2009:504897
34. Zadrazil J (2006) Nonsteroidal anti-inflammatory drugs and the kidney. Vnitr Lek 52:686-690